Adezunap

Pain Syndrome

Apurano Pharmaceuticals GmbHPhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 95/ 100

Competitive context

3 Active assets in the Pain Syndrome cohort.

Asset / Sponsor	Phase	Rating
DEXAMETHASONE Ottawa Hospital Research Institute	Phase 4	BB
TRIATOMIC OXYGEN Bernardino Clavo, MD, PhD	Phase 2/3	B
Etoricoxib Guangdong Provincial People's Hospital	Phase 2	B
Marijuana University of California, San Diego	Phase 2	B
Oxygen Bernardino Clavo, MD, PhD	Phase 2/3	B

View all 10 →

Same molecule, other indications

Adezunap is also rated in:

Post Operative PainDormant

B

Indicative ·

60 / 100

Central Neuropathic PainDormant

B

Indicative ·

60 / 100

vertebral column disorderDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.